Dopamine agonist withdrawal syndrome (DAWS). That is its name. Named in the literature since 2010. Diagnostic criteria exist. It affects, by conservative estimate, one in five to one in four patients who taper off these drugs. This is not a mystery ailment. It is a known, foreseeable medical injury, and foreseeable harm that goes unwarned and unmonitored is not bad luck. It is a failure of duty. If this profession takes its oath seriously (first, do no harm), then knowing this syndrome exists and failing to warn, screen, or monitor for it is a choice, repeated on person after person.
I am one of those patients. I augmented on the dopamine agonist I was prescribed as a diagnostic tool. “Maybe you have restless legs, take this and if it works we’ll know the answer” should never have happened in 2018, eight years after augmentation and DAWS were already recognized. I spent the past couple of years building a language for what happens in the body when the nervous system is overwhelmed. I built it because I needed it. It still wasn’t enough to get me through what withdrawal did to my emotional architecture. Willpower, insight, and contemplative practice should not have to be enough. It is not the standard we hold anywhere else in medicine.
Most patients have no such language at all. They are simply reacting, in real time, to what their nervous system is telling them, with no framework to slow it down and no idea that what’s happening to them is a known syndrome rather than a personal collapse. Now follow that person forward: They lose their temper at work, not because of who they are, but because of a withdrawal that was a foreseeable possibility their doctor never communicated or prepared them for. They’re written up, or fired. With the job goes the insurance. Without insurance, they don’t come back. From your side of the chart, they simply disappeared: non-compliant, lost to follow-up. From their side, one dysregulated moment cost them everything, one piece at a time.
The mental health crisis DAWS produces looks, from the outside and often from the inside, like the crisis presentation seen in active addiction and severe mental illness: the agitation, the volatility, the erratic behavior. That is not coincidence; the withdrawal mechanism echoes stimulant withdrawal for a documented reason. So how do these people get treatment? How does someone who has lost their job, insurance, and footing to a prescription drug injury even know to ask for help? There is a specific terror in realizing you are one taper away from becoming the person your own culture has taught you to fear, not because of anything you did, but because of something done to you, by someone you trusted with your life.
Real physician voices, twice a week
Free, and one click to unsubscribe.
The clinical facts are not in dispute. You know dopamine agonists act on the same reward pathways implicated in stimulant addiction. You know the symptom list: anxiety, panic attacks, depression, agitation, suicidal ideation, autonomic symptoms, drug cravings. You know some patients recover in weeks; others carry this for years. You know DAWS is refractory to levodopa, other dopaminergic therapies, antidepressants, and antipsychotics; there is no established treatment once it takes hold, only guidance on trying to prevent it. And you know the recommended response has been written into clinical guidance for over a decade: Use these drugs judiciously, warn patients before starting, monitor closely, taper at the first sign of trouble.
This letter is not asking you to discover something. It’s asking why knowing hasn’t translated into doing, and why so little research funding has gone toward finding a treatment for a syndrome this common, more than fifteen years after it was named.
This applies as much to restless legs syndrome (RLS) as to Parkinson’s. RLS patients are often managed outside movement disorder clinics, with even less oversight during a taper, and dopamine agonists prescribed for RLS carry their own trap: augmentation, an iatrogenic worsening of symptoms affecting an estimated 7 to 10 percent of patients annually. The American Academy of Sleep Medicine has already reversed course on dopamine agonists as first-line RLS treatment for this reason. That guidance exists. The question is whether it’s reaching patients before they’re prescribed a drug that could trap them twice.
You cannot expect a person in an altered, destabilized state to self-advocate clearly enough to be believed, using the very executive function the withdrawal is disrupting. That is a design flaw, not a patient failure. They need a support person. They need an external pathway to being understood, built into the system, not left to chance.
What I am asking for:
- Informed consent that includes withdrawal risk, not just side effects, before a patient ever starts.
- A taper protocol that assumes risk by default, not one that waits for the patient to report distress first.
- A bridge to in-the-moment support during the taper window, not just a follow-up appointment weeks later.
- Communication between neurology and primary care, so patients aren’t the sole carriers of their own medical narrative.
- Belief. A presentation matching a documented syndrome should be met with recognition, not skepticism.
- Real investment in a DAWS treatment, not just prevention. Prevention does nothing for patients already living inside it.
- Adherence to existing RLS guidance (iron repletion and gabapentinoids before dopamine agonists), so fewer patients ever need a DAWS protocol at all.
None of this is radical. Most of it is already written into your own field’s guidance. What’s missing is follow-through, treating every taper as a real risk from the start, not after the crisis.
I don’t write this from anger alone, though there is anger in it. Most of you did not choose this gap on purpose. It is a systemic failure of time, attention, and infrastructure, fixable, because the knowledge already exists. What’s missing is the will to build medicine around the patient about to fall, not the one who’s already hit the ground.
We are not asking you to solve what has no solution yet. We are asking you to stop leaving us to find that out alone.
Jessica Fausnaugh is a patient advocate.
